{"id":"W2153921055","doi":"10.1158/1078-0432.ccr-08-0529","title":"Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Rituximab; Medicine; Chemoimmunotherapy; Radioimmunotherapy; Follicular lymphoma; Ibritumomab tiuxetan; CHOP; Nuclear medicine; Vincristine; Lymphoma; Internal medicine; Gastroenterology; Cyclophosphamide; Chemotherapy; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002219845,0.00127454,0.001693977,0.0002980073,0.0004024035,0.000609152,0.0008505515,0.001038737,0.002593371],"category_scores_gemma":[0.001348714,0.0005288409,0.0008029791,0.0002756339,0.001058015,0.0007133714,0.0003764383,0.002341762,0.0006026214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008148724,"about_ca_system_score_gemma":0.001292206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007564977,"about_ca_topic_score_gemma":0.001189309,"domain_scores_codex":[0.9993516,0.0003910614,0.00003460226,0.0000861871,0.00004357561,0.00009308345],"domain_scores_gemma":[0.9987642,0.000258864,0.0002618123,0.000116424,0.00005502648,0.0005436919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8831716,0.05252491,0.005250055,0.0002996602,0.0006064929,0.0002048256,0.0002154635,0.001486028,0.01627867,0.0001203899,0.0009654985,0.03887635],"study_design_scores_gemma":[0.5898954,0.398741,0.006890701,0.00002329185,0.0001725429,0.0001895415,0.00003435537,0.001037658,0.002074251,0.00006103981,0.000866052,0.00001410396],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974662,0.0006989626,0.0002401484,0.0001403006,0.0000598028,0.0008763754,0.000119423,0.00003391481,0.0003648217],"genre_scores_gemma":[0.994922,0.0005273999,0.0008954168,0.0003588497,0.0001612723,0.001504751,0.0007168317,0.00001205615,0.0009013577],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002593371,"threshold_uncertainty_score":0.01173979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1457220537021659,"score_gpt":0.4981432744785355,"score_spread":0.3524212207763696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}